Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694

Journal of Biological Chemistry

Volumn 290, Issue 10, 2015, Pages 5960-5978

  Zhong, Yiming ^a   Dong, Shuai ^b   Strattan, Ethan ^a   Ren, Li ^a   Butchar, Jonathan P ^a   Thornton, Kelsey ^a   Mishra, Anjali ^a   Porcu, Pierluigi ^a   Michael Bradshaw, J ^c   Bisconte, Angelina ^c   Owens, Timothy D ^c   Verner, Erik ^c   Brameld, Ken A ^c   Funk, Jens Oliver ^c   Hill, Ronald J ^c   Johnson, Amy J ^a   Dubovsky, Jason A ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Principia Biopharma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CHEMICAL ACTIVATION; CYTOLOGY; DISEASE CONTROL; ENZYMES; LYMPHOCYTES; T-CELLS;

EFFECTIVE THERAPY; EFFECTIVE TOOL; IMMUNE ACTIVATION; INTERLEUKIN-2; MALIGNANT DISEASE; NK CELLS;

CELL SIGNALING;

ADENOSINE TRIPHOSPHATE; BRUTON TYROSINE KINASE INHIBITOR; CALCIUM; CYSTEINE; CYSTEINE 442; CYTOKINE; FC RECEPTOR; IBRUTINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 INDUCIBLE T CELL KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE; PLECKSTRIN; PRN 694; PROTEIN KINASE INHIBITOR; RESTING LYMPHOCYTE KINASE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; BENZIMIDAZOLE DERIVATIVE; EMT PROTEIN-TYROSINE KINASE; LYMPHOCYTE ANTIGEN RECEPTOR; PRN694; PROTEIN TYROSINE KINASE; TEC PROTEIN-TYROSINE KINASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CALCIUM TRANSPORT; CELL ACTIVATION; CONTROLLED STUDY; COVALENT BOND; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MAST CELL; MOLECULAR MODEL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; PROTEIN DOMAIN; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH17 CELL; TH2 CELL; THYMOCYTE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; SIGNAL TRANSDUCTION; X RAY CRYSTALLOGRAPHY;

ADENOSINE TRIPHOSPHATE; BENZIMIDAZOLES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; CYSTEINE; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84924794877     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.614891     Document Type: Article

References (68)

1. Felices, M., and Berg, L. J. (2008) The Tec kinases Itk and Rlk regulate NKT cell maturation, cytokine production, and survival. J. Immunol. 180, 3007-3018
2. Khurana, D., Arneson, L. N., Schoon, R. A., Dick, C. J., and Leibson, P. J. (2007) Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk. J. Immunol. 178, 3575-3582
3. Schaeffer, E. M., Debnath, J., Yap, G., McVicar, D., Liao, X. C., Littman, D. R., Sher, A., Varmus, H. E., Lenardo, M. J., and Schwartzberg, P. L. (1999) Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity. Science 284, 638-641
4. Berg, L. J., Finkelstein, L. D., Lucas, J. A., and Schwartzberg, P. L. (2005) Tec family kinases in T lymphocyte development and function. Annu. Rev. Immunol. 23, 549-600
5. Finkelstein, L. D., Shimizu, Y., and Schwartzberg, P. L. (2005) Tec kinases regulate TCR-mediated recruitment of signaling molecules and integrindependent cell adhesion. J. Immunol. 175, 5923-5930
6. Readinger, J. A., Mueller, K. L., Venegas, A. M., Horai, R., and Schwartzberg, P. L. (2009) Tec kinases regulate T-lymphocyte development and function: new insights into the roles of Itk and Rlk/Txk. Immunol. Rev. 228, 93-114
7. + T cells. Immunity 11, 399-409
8. Mueller, C., and August, A. (2003) Attenuation of immunological symptoms of allergic asthma in mice lacking the tyrosine kinase ITK. J. Immunol. 170, 5056-5063
9. Gomez-Rodriguez, J., Wohlfert, E. A., Handon, R., Meylan, F., Wu, J. Z., Anderson, S. M., Kirby, M. R., Belkaid, Y., and Schwartzberg, P. L. (2014) Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells. J. Exp. Med. 211, 529-543
10. Papp, K. A., Leonardi, C., Menter, A., Ortonne, J. P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H., and Baumgartner, S. (2012) Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366, 1181-1189
11. Waite, J. C., and Skokos, D. (2012) Th17 response and inflammatory autoimmune diseases. Int. J. Inflam. 2012, 819467
12. Kannan, Y., and Wilson, M. S. (2012) TEC and MAPK kinase signalling pathways in T helper (T) cell development, T2 differentiation and allergic asthma. J. Clin. Cell. Immunol. 12, 11
13. Gomez-Rodriguez, J., Sahu, N., Handon, R., Davidson, T. S., Anderson, S. M., Kirby, M. R., August, A., and Schwartzberg, P. L. (2009) Differential expression of interleukin-17A and -17F is coupled to T cell receptor signaling via inducible T cell kinase. Immunity 31, 587-597
14. Ferrara, T. J., Mueller, C., Sahu, N., Ben-Jebria, A., and August, A. (2006) Reduced airway hyperresponsiveness and tracheal responses during allergic asthma in mice lacking tyrosine kinase inducible T-cell kinase. J. Allergy Clin. Immunol. 117, 780-786
15. Vargas, L., Hamasy, A., Nore, B. F., and Smith, C. I. (2013) Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases. Scand. J. Immunol. 78, 130-139
16. Warner, K., Crispatzu, G., Al-Ghaili, N., Weit, N., Florou, V., You, M. J., Newrzela, S., and Herling, M. (2013) Models for mature T-cell lymphomas: a critical appraisal of experimental systems and their contribution to current T-cell tumorigenic concepts. Crit. Rev. Oncol. Hematol. 88, 680-695
17. Warner, K., Weit, N., Crispatzu, G., Admirand, J., Jones, D., and Herling, M. (2013) T-cell receptor signaling in peripheral T-cell lymphoma: a review of patterns of alterations in a central growth regulatory pathway. Curr. Hematol. Malig. Rep. 8, 163-172
18. Alder, C. M., Ambler, M., Campbell, A. J., Champigny, A. C., Deakin, A. M., Harling, J. D., Harris, C. A., Longstaff, T., Lynn, S., Maxwell, A. C., Mooney, C. J., Scullion, C., Singh, O. M., Smith, I. E., Somers, D. O., Tame, C. J., Wayne, G., Wilson, C., and Woolven, J. M. (2013) Identification of a novel and selective series of Itk inhibitors via a template-hopping strategy. ACS Med. Chem. Lett. 4, 948-952
19. Charrier, J. D., Miller, A., Kay, D. P., Brenchley, G., Twin, H. C., Collier, P. N., Ramaya, S., Keily, S. B., Durrant, S. J., Knegtel, R. M., Tanner, A. J., Brown, K., Curnock, A. P., and Jimenez, J. M. (2011) Discovery and struc-ture- activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors. J. Med. Chem. 54, 2341-2350
20. McLean, L. R., Zhang, Y., Zaidi, N., Bi, X., Wang, R., Dharanipragada, R., Jurcak, J. G., Gillespy, T. A., Zhao, Z., Musick, K. Y., Choi, Y. M., Barrague, M., Peppard, J., Smicker, M., Duguid, M., Parkar, A., Fordham, J., and Kominos, D. (2012) X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase. Bioorg. Med. Chem. Lett. 22, 3296-3300
21. Pastor, R. M., Burch, J. D., Magnuson, S., Ortwine, D. F., Chen, Y., De La Torre, K., Ding, X., Eigenbrot, C., Johnson, A., Liimatta, M., Liu, Y., Shia, S., Wang, X., Wu, L. C., and Pei, Z. (2014) Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors. Bioorg. Med. Chem. Lett. 24, 2448-2452
22. Moriarty, K. J., Takahashi, H., Pullen, S. S., Khine, H. H., Sallati, R. H., Raymond, E. L., Woska, J. R., Jr., Jeanfavre, D. D., Roth, G. P., Winters, M. P., Qiao, L., Ryan, D., DesJarlais, R., Robinson, D., Wilson, M., Bobko, M., Cook, B. N., Lo, H. Y., Nemoto, P. A., Kashem, M. A., Wolak, J. P., White, A., Magolda, R. L., and Tomczuk, B. (2008) Discovery, SAR and x-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk). Bioorg. Med. Chem. Lett. 18, 5545-5549
23. Han, S., Czerwinski, R. M., Caspers, N. L., Limburg, D. C., Ding, W., Wang, H., Ohren, J. F., Rajamohan, F., McLellan, T. J., Unwalla, R., Choi, C., Parikh, M. D., Seth, N., Edmonds, J., Phillips, C., Shakya, S., Li, X., Spaulding, V., Hughes, S., Cook, A., Robinson, C., Mathias, J. P., Navratilova, I., Medley, Q. G., Anderson, D. R., Kurumbail, R. G., and Aulabaugh, A. (2014) Selectively targeting an inactive conformation of interleukin-2- inducible T-cell kinase by allosteric inhibitors. Biochem. J. 460, 211-222
24. Carpenter, R. L., and Lo, H. W. (2012) Dacomitinib, an emerging HERtargeted therapy for non-small cell lung cancer. J. Thorac. Dis. 4, 639-642
25. Serafimova, I. M., Pufall, M. A., Krishnan, S., Duda, K., Cohen, M. S., Maglathlin, R. L., McFarland, J. M., Miller, R. M., Frödin, M., and Taunton, J. (2012) Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles. Nat. Chem. Biol. 8, 471-476
26. Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., Johnson, A. J., Sukbuntherng, J., Chang, B. Y., Clow, F., Hedrick, E., Buggy, J. J., James, D. F., and O'Brien, S. (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32-42
27. Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreyling, M., Jedrzejczak, W. W., Johnson, P., Spurgeon, S. E., Li, L., Zhang, L., Newberry, K., Ou, Z., Cheng, N., Fang, B., McGreivy, J., Clow, F., Buggy, J. J., Chang, B. Y., Beaupre, D. M., Kunkel, L. A., and Blum, K. A. (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369, 507-516
28. Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T. M., Chang, B. Y., Larkin, K. M., Stefanovski, M. R., Chappell, D. L., Frissora, F. W., Smith, L. L., Smucker, K. A., Flynn, J. M., Jones, J. A., Andritsos, L. A., Maddocks, K., Lehman, A. M., Furman, R., Sharman, J., Mishra, A., Caligiuri, M. A., Satoskar, A. R., Buggy, J. J., Muthusamy, N., Johnson, A. J., and Byrd, J. C. (2013) Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes. Blood 122, 2539-2549
29. Pfaffl, M. W. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45
30. Dubovsky, J. A., McNeel, D. G., Powers, J. J., Gordon, J., Sotomayor, E. M., and Pinilla-Ibarz, J. A. (2009) Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin. Cancer Res. 15, 3406-3415
31. + tumor cells. Clin. Cancer Res. 14, 4650-4657
32. Zhong, Y., Sullenbarger, B., and Lasky, L. C. (2010) Effect of increased HoxB4 on human megakaryocytic development. Biochem. Biophys. Res. Commun. 398, 377-382
33. Susaki, K., Kitanaka, A., Dobashi, H., Kubota, Y., Kittaka, K., Kameda, T., Yamaoka, G., Mano, H., Mihara, K., and Ishida, T. (2010) Tec protein tyrosine kinase inhibits CD25 expression in human T-lymphocyte. Immunol. Lett. 127, 135-142
34. Bergamini, G., Bell, K., Shimamura, S., Werner, T., Cansfield, A., Müller, K., Perrin, J., Rau, C., Ellard, K., Hopf, C., Doce, C., Leggate, D., Mangano, R., Mathieson, T., O'Mahony, A., Plavec, I., Rharbaoui, F., Reinhard, F., Savitski, M. M., Ramsden, N., Hirsch, E., Drewes, G., Rausch, O., Bantscheff, M., and Neubauer, G. (2012) A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation. Nat. Chem. Biol. 8, 576-582
35. Melton, A. C., Melrose, J., Alajoki, L., Privat, S., Cho, H., Brown, N., Plavec, A. M., Nguyen, D., Johnston, E. D., Yang, J., Polokoff, M. A., Plavec, I., Berg, E. L., and O'Mahony, A. (2013) Regulation of IL-17A production is distinct from IL-17F in a primary human cell co-culture model of T cell-mediated B cell activation. PLoS One 8, e58966
36. Xu, D., Kim, Y., Postelnek, J., Vu, M. D., Hu, D. Q., Liao, C., Bradshaw, M., Hsu, J., Zhang, J., Pashine, A., Srinivasan, D., Woods, J., Levin, A., O'Mahony, A., Owens, T. D., Lou, Y., Hill, R. J., Narula, S., DeMartino, J., and Fine, J. S. (2012) RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J. Pharmacol. Exp. Ther. 341, 90-103
37. Lin, T. A., McIntyre, K. W., Das, J., Liu, C., O'Day, K. D., Penhallow, B., Hung, C. Y., Whitney, G. S., Shuster, D. J., Yang, X., Townsend, R., Postelnek, J., Spergel, S. H., Lin, J., Moquin, R. V., Furch, J. A., Kamath, A. V., Zhang, H., Marathe, P. H., Perez-Villar, J. J., Doweyko, A., Killar, L., Dodd, J. H., Barrish, J. C., Wityak, J., and Kanner, S. B. (2004) Selective Itk inhibitors block T-cell activation and murine lung inflammation. Biochemistry 43, 11056-11062
38. Andreotti, A. H., Schwartzberg, P. L., Joseph, R. E., and Berg, L. J. (2010) T-cell signaling regulated by the Tec family kinase, Itk. Cold Spring Harb. Perspect. Biol. 2, a002287
39. Alter, G., Malenfant, J. M., and Altfeld, M. (2004) CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294, 15-22
40. Cohnen, A., Chiang, S. C., Stojanovic, A., Schmidt, H., Claus, M., Saftig, P., Janssen, O., Cerwenka, A., Bryceson, Y. T., and Watzl, C. (2013) Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage. Blood 122, 1411-1418
41. Köprülü, A. D., Kastner, R., Wienerroither, S., Lassnig, C., Putz, E. M., Majer, O., Reutterer, B., Sexl, V., Kuchler, K., Müller, M., Decker, T., and Ellmeier, W. (2013) The tyrosine kinase Btk regulates the macrophage response to Listeria monocytogenes infection. PLoS One 8, e60476
42. Kosaka, Y., Felices, M., and Berg, L. J. (2006) Itk and Th2 responses: action but no reaction. Trends Immunol. 27, 453-460
43. Horwood, N. J., Urbaniak, A. M., and Danks, L. (2012) Tec family kinases in inflammation and disease. Int. Rev. Immunol. 31, 87-103
44. rd (2013) Th17 cells in immunity and autoimmunity. Clin. Dev. Immunol. 2013, 986789
45. Galli, S. J., and Hammel, I. (1984) Unequivocal delayed hypersensitivity in mast cell-deficient and beige mice. Science 226, 710-713
46. Liao, X. C., and Littman, D. R. (1995) Altered T cell receptor signaling and disrupted T cell development in mice lacking Itk. Immunity 3, 757-769
47. Liu, K. Q., Bunnell, S. C., Gurniak, C. B., and Berg, L. J. (1998) T cell receptor-initiated calcium release is uncoupled from capacitative calcium entry in Itk-deficient T cells. J. Exp. Med. 187, 1721-1727
48. Sahu, N., and August, A. (2009) ITK inhibitors in inflammation and im-mune- mediated disorders. Curr. Top. Med. Chem. 9, 690-703
49. Lowes, M. A., Kikuchi, T., Fuentes-Duculan, J., Cardinale, I., Zaba, L. C., Haider, A. S., Bowman, E. P., and Krueger, J. G. (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 128, 1207-1211
50. Uyemura, K., Yamamura, M., Fivenson, D. F., Modlin, R. L., and Nickoloff, B. J. (1993) The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J. Invest. Dermatol. 101, 701-705
51. Zaba, L. C., Fuentes-Duculan, J., Eungdamrong, N. J., Abello, M. V., Novitskaya, I., Pierson, K. C., Gonzalez, J., Krueger, J. G., and Lowes, M. A. (2009) Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J. Invest. Dermatol. 129, 79-88
52. Kobayashi, T., Okamoto, S., Hisamatsu, T., Kamada, N., Chinen, H., Saito, R., Kitazume, M. T., Nakazawa, A., Sugita, A., Koganei, K., Isobe, K., and Hibi, T. (2008) IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 57, 1682-1689
53. Hundorfean, G., Neurath, M. F., and Mudter, J. (2012) Functional relevance of T helper 17 (Th17) cells and the IL-17 cytokine family in inflammatory bowel disease. Inflamm. Bowel Dis. 18, 180-186
54. Brand, S. (2009) Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 58, 1152-1167
55. Shen, H., Goodall, J. C., and Hill Gaston, J. S. (2009) Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 60, 1647-1656
56. Hirota, K., Yoshitomi, H., Hashimoto, M., Maeda, S., Teradaira, S., Sugimoto, N., Yamaguchi, T., Nomura, T., Ito, H., Nakamura, T., Sakaguchi, N., and Sakaguchi, S. (2007) Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J. Exp. Med. 204, 2803-2812
57. Iyer, A. S., Morales, J. L., Huang, W., Ojo, F., Ning, G., Wills, E., Baines, J. D., and August, A. (2011) Absence of Tec family kinases interleukin-2 inducible T cell kinase (Itk) and Bruton's tyrosine kinase (Btk) severely impairs Fc∈RI-dependent mast cell responses. J. Biol. Chem. 286, 9503-9513
58. Kawakami, Y., Yao, L., Tashiro, M., Gibson, S., Mills, G. B., and Kawakami, T. (1995) Activation and interaction with protein kinase C of a cytoplasmic tyrosine kinase, Itk/Tsk/Emt, on Fc∈RI cross-linking on mast cells. J. Immunol. 155, 3556-3562
59. Das, J., Furch, J. A., Liu, C., Moquin, R. V., Lin, J., Spergel, S. H., McIntyre, K. W., Shuster, D. J., O'Day, K. D., Penhallow, B., Hung, C. Y., Doweyko, A. M., Kamath, A., Zhang, H., Marathe, P., Kanner, S. B., Lin, T. A., Dodd, J. H., Barrish, J. C., and Wityak, J. (2006) Discovery and SAR of 2-amino- 5-(thioaryl)thiazoles as potent and selective Itk inhibitors. Bioorg. Med. Chem. Lett. 16, 3706-3712
60. Guo, W., Liu, R., Ono, Y., Ma, A. H., Martinez, A., Sanchez, E., Wang, Y., Huang, W., Mazloom, A., Li, J., Ning, J., Maverakis, E., Lam, K. S., and Kung, H. J. (2012) Molecular characteristics of CTA056, a novel interleu-kin- 2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs. Mol. Pharmacol. 82, 938-947
61. Snow, R. J., Abeywardane, A., Campbell, S., Lord, J., Kashem, M. A., Khine, H. H., King, J., Kowalski, J. A., Pullen, S. S., Roma, T., Roth, G. P., Sarko, C. R., Wilson, N. S., Winters, M. P., Wolak, J. P., and Cywin, C. L. (2007) Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors. Bioorg. Med. Chem. Lett. 17, 3660-3665
62. Velankar, A. D., Quintini, G., Prabhu, A., Weber, A., Hunaeus, G., Voland, B., Wuest, M., Orjeda, C., Harel, D., Varghese, S., Gore, V., Patil, M., Gayke, D., Herdemann, M., Heit, I., and Zaliani, A. (2010) Synthesis and biological evaluation of novel (4 or 5-aryl)pyrazolyl-indoles as inhibitors of interleukin-2 inducible T-cell kinase (ITK). Bioorg. Med. Chem. 18, 4547-4559
63. Pan, Z., Scheerens, H., Li, S. J., Schultz, B. E., Sprengeler, P. A., Burrill, L. C., Mendonca, R. V., Sweeney, M. D., Scott, K. C., Grothaus, P. G., Jeffery, D. A., Spoerke, J. M., Honigberg, L. A., Young, P. R., Dalrymple, S. A., and Palmer, J. T. (2007) Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. Chem. Med. Chem. 2, 58-61
64. Harling, J. D., Deakin, A. M., Campos, S., Grimley, R., Chaudry, L., Nye, C., Polyakova, O., Bessant, C. M., Barton, N., Somers, D., Barrett, J., Graves, R. H., Hanns, L., Kerr, W. J., and Solari, R. (2013) Discovery of novel irreversible inhibitors of interleukin (IL)-2-inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket. J. Biol. Chem. 288, 28195-28206
65. Kaukonen, J., Savolainen, E. R., and Palotie, A. (1999) Human Emt tyrosine kinase is specifically expressed both in mature T-lymphocytes and T-cell associated hematopoietic malignancies. Leuk. Lymphoma 32, 513-522
66. Shin, J., Monti, S., Aires, D. J., Duvic, M., Golub, T., Jones, D. A., and Kupper, T. S. (2007) Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood 110, 3015-3027
67. Zhao, W. L. (2010) Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. Leukemia 24, 13-21
68. Brameld, K. A., and Owens, T. A. (March 6, 2014) International Patent WO 2014/036016 A1